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Crohn’s disease (CD) is a systemic chronic inflammatory condition mainly characterized 
by discontinuous transmural pathology of the gastrointestinal tract and frequent extrain-
testinal manifestations with intermittent episodes of remission and relapse. Genome-
wide association studies identified a number of risk loci that, catalyzed by environmental 
triggers, result in the loss of tolerance toward commensal bacteria based on dysregulated 
innate effector functions and antimicrobial defense, leading to exacerbated adaptive 
immune responses responsible for chronic immune-mediated tissue damage. In this 
review, we discuss the inter-related role of changes in the intestinal microbiota, epithelial 
barrier integrity, and immune cell functions on the pathogenesis of CD, describing the 
current approaches available to investigate the molecular mechanisms underlying the 
disease. Substantial effort has been dedicated to define disease-associated changes in 
the intestinal microbiota (dysbiosis) and to link pathobionts to the etiology of inflamma-
tory bowel diseases. A cogent definition of dysbiosis is lacking, as well as an agreement 
of whether pathobionts or complex shifts in the microbiota trigger inflammation in the 
host. Among the rarely available animal models, SAMP/Yit and TNFdeltaARE mice are the 
best known displaying a transmural CD-like phenotype. New hypothesis-driven mouse 
models, e.g., epithelial-specific Caspase8−/−, ATG16L1−/−, and XBP1−/− mice, validate 
pathway-focused function of specific CD-associated risk genes highlighting the role 
of Paneth cells in antimicrobial defense. To study the causal role of bacteria in initi-
ating inflammation in the host, the use of germ-free mouse models is indispensable. 
Unraveling the interactions of genes, immune cells and microbes constitute a criterion 
for the development of safe, reliable, and effective treatment options for CD.
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iNTRODUCTiON
Crohn’s disease (CD) is one of the two dominant phenotypes of inflammatory bowel diseases (IBD) 
characterized by chronic and relapsing inflammation of intestinal segments (1). There is overwhelm-
ing evidence corroborating the notion that the pathophysiology of CD is under the control of several 
contributing factors, including heritable traits, environmental cues, abnormalities in intestinal 
mucosal barrier integrity (2) and function (3), immune regulation (4, 5), and gut microbiota (6). 
Exaggerated immune responses are presumably directed against normal commensal enteric bacteria 
in genetically susceptible hosts. Host genetic susceptibility may be related to defective mucosal barrier 
November 2015 | Volume 6 | Article 5552
Buttó et al. Dysbiosis vs. Pathobiont Selection in Crohn’s Disease
Frontiers in Immunology | www.frontiersin.org
function and/or bacterial killing, leading to an overexposure to 
luminal antigens and to inadequate immunoregulation, resulting 
in abnormal responses and tissue damage (7–11).
GeNeTiC eviDeNCe FOR  
MiCROBe–HOST iNTeRACTiON 
iN CROHN’S DiSeASe
Genome-wide association studies (GWAS) have postulated 
that the heritability of IBD may arise from polymorphisms 
in associated genes, each contributing in an additive fashion 
to the overall disease risk (12–15). The most recent GWAS 
meta-analysis has ascertained 163 susceptibility loci for IBD, 
revealing similar genetic predispositions in childhood and adult 
onsets (15). A number of these genetic risk factors are related 
to innate immunity, most specifically to microbial recognition 
and its subsequent elimination. The first susceptibility gene 
described and associated to increased risk of developing CD in 
Caucasian populations is the nucleotide-binding oligomeriza-
tion domain 2 (NOD2, also called CARD15) gene. NOD2 gene 
encodes a cytoplasmic pathogen-recognition receptor (PRR) 
that recognizes muramyldipeptide (MDP), a component of 
both Gram-positive and Gram-negative cell walls, and there-
fore it is thought to play a role in the clearance of intracellular 
bacteria (16–20).
Additional CD-susceptibility genes that affect bacterial 
killing include autophagy-related protein 16-1 (ATG16L1) 
and immunity-related GTPase M (IRGM) (21–26). ATG16L1 
gene encodes for an integral protein of the autophagy path-
way. Autophagy is an important host defense mechanism for 
handling intracellular microorganisms and for the response 
to cellular stress, and it requires the generation of curved 
membranes to envelop cytoplasmic organelles and intracel-
lular pathogens (27). A working hypothesis is that variants 
in components of the autophagy machinery may result in 
reduced pathogen clearance and intracellular homeostasis. 
IRGM gene encodes for one of the IRG proteins that orches-
trate immunity toward intracellular pathogens including 
autophagy functions (28). While Irgm-deficient mice do not 
consistently exhibit spontaneous intestinal inflammation, 
they are much more susceptible to dextrate sodium sulfate 
(DSS) colitis compared to the WT counterparts, developing 
acute epithelial injury, loss of Paneth cell granules, altered 
antimicrobial peptide (AMP) production, and authophagy 
function of the epithelium (29).
Further CD-susceptibility loci related to aberrant micro-
bial recognition and handling encompass toll-like receptor 4 
(TLR4) (30), leucine-rich repeat kinase-2 (LRRK2) (31), and 
neutrophil cytosolic factor-4 (NCF4) (25). TLR4 is critical for 
host defense against Gram-negative bacteria since it recognizes 
lipopolysaccharide (LPS), and it is expressed on intestinal 
epithelial cells (IECs) and myeloid cells, such as macrophages 
(MΦs) and dendritic cells (DCs) (32). Two single nucleotide 
polymorphisms of human TLR4, D299G, and T399I lead to 
hyporesponsiveness to LPS by interfering with recruitment 
of TLR adapter molecules, such as myeloid differentiation 
primary response 88 (MYD88) and TIR domain-containing 
adaptor-inducing interferon β (TRIF) (33–35). LRRK2 gene is 
highly expressed on bone marrow-derived myeloid cells, but 
it is not expressed in IECs (36). Lrrk2-deficient mice do not 
develop spontaneous inflammation, but they are more suscep-
tible to DSS experimental colitis compared to WT littermates, 
suggesting a role for innate immune cells in IBD progression 
(37). NCF4 encodes the p40-phox subunit of nicotinamide 
adenine dinucleotide phosphate oxidase that is crucial for 
reactive oxygen species (ROS) production by phagocytic cells 
in response to microbial infection. Genetic alterations in this 
CD-susceptibility gene result in abnormal neutrophil and MΦ 
recruitment, exacerbated cytokine secretion, impaired ROS 
production, and reduced bacterial clearance in CD patients 
(38, 39).
A proposed mechanism for the pathogenesis of CD is an exag-
gerated T (TH1/TH17) cell response toward luminal microbiota, 
which results in the breakdown of the mucosal tolerance to enteric 
bacteria (40). High levels of antibodies against these microbes 
correlate with disease progression, and TH1 and TH17 cells are 
massively recruited to mucosal sites and secrete cytokines, such 
as TNF-α, IFN-γ, IL-17, and IL-22, which participate to the 
inflammatory state in CD patients (41–45). GWAS indicated that 
IL-23 receptor gene and five additional genes involved in TH17 
differentiation (IL12B, JAK2, STAT3, CCR6, and TNFSF15) are 
associated with susceptibility to CD (40). Anti-IL-12/IL-23 anti-
body therapy, which targets both TH1 and TH17 cells, is effective 
in CD (42, 46). Finally, the exact specificity of these T cells, their 
pathways of activation, and the mechanisms of their dysfunc-
tion in CD are still poorly understood. These aspects have been 
elegantly discussed by others (47, 48) and will not be examined 
in the current review.
Compelling evidence regarding the marginal role of herit-
able traits in triggering the onset and causing flares in CD 
has been provided by GWAS with monozygotic twin cohorts. 
Monozygotic twins have an (almost) identical genetic make-
up, and they also have presumably similar environmental 
exposure and dietary habits in early childhood. They also have 
a similar gut microbial composition when healthy (49). Despite 
familial aggregation being a risk factor for developing IBD 
(2, 50), germline variation in CD loci of monozygotic twins 
only accounts for ~25% of estimated heritability, suggesting 
that the contribution of genetic factors to the etiology of CD 
is modest (51, 52). Differential exposure to environmental 
factors (so-called exposome) might account for the low level 
of concordance in monozygotic twins. Another working 
hypothesis is that T and B cell receptors (TCRs and BCRs) are 
not identical in monozygotic twins and that specific receptor 
rearrangements predispose to an immune-related sensitivity 
or autoimmune disease (53). In addition, a potential reason 
for relatively low concordance rates in monozygotic twins may 
relate to epigenetic changes. The study by Satsangi’s research 
team provides compelling evidence for epigenic modifications 
in several regions of the genome of pediatric and adult CD 
patients (54, 55).
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SeNSiNG OF MiCROBeS
Good fences make good neighbors
  (Robert Frost, 1914) (56)
The mammalian intestine is inhabited by complex bacterial com-
munities that contribute to the host metabolism and immunity. It 
remains under investigation how the host maintains homeostasis 
toward these bacterial populations, discriminating between com-
mensal and pathogenic bacteria-derived signals. A growing body 
of evidence suggests that IECs contribute to mucosal homeostasis 
through the integration of microbial signals and interaction with 
immunocompetent cells (57). Current hypotheses suggest that 
the breakdown of the intestinal epithelial barrier function leads to 
increased translocation of food and bacterial antigens, to loss of 
immune tolerance to commensal bacteria, and to chronic intesti-
nal inflammation, triggering the onset of CD. IECs contribute to 
tissue homeostasis by maintaining a rigorous spatial separation 
between microbiota and host, which limits immune activation 
and promotes induction of tolerance. Specialized IECs may sense 
the intestinal bacterial community through PRRs, such as TLRs 
and NOD receptor, and preserve mucosal homeostasis exploit-
ing several strategies to restrict the colonization of resident and 
pathogenic bacteria and avoid immune overactivation. Processes 
engaged to this end encompass the secretion of an apical mucus 
layer by globlet cells (58), the secretion of AMPs by Paneth cells 
(59, 60), and the transport of secretory immunoglobulin across 
the epithelial barrier (61, 62). Mucus production has been shown 
to increase in germ-free (GF) mice exposed to TLR ligands, sug-
gesting that bacteria-derived signals regulate goblet cell functions 
(58). Paneth cells are specialized cells in the crypts of the small 
intestine from which they exert a role in crypt homeostasis and 
maintenance of the intestinal stem-cell niche by secreting AMPs 
that keeps commensal and pathogenic bacteria at bay and regulate 
the composition of the gut microflora (63, 64). The expression of 
AMPs, such as RegIIIγ, is dependent on the recognition of bacte-
rial molecules through Myd88-dependent TLR sensing. Evidence 
of this mechanism is provided by the proof that epithelial cell-
specific Myd88-knockout mice and RegIIIγ-knockout mice loose 
the segregation between the microbiota and the intestinal surface, 
leading to a dramatic increase in mucosal-associated bacteria in 
the terminal ileum (65). Similar loss in spatial organization has 
been observed in biopsies from CD patients, characterized by 
lower AMP levels and consequently increased mucolytic bacteria 
and compromised mucus layer (66–68). Similarly, Muc2-deficient 
mice develop spontaneous colitis (69).
Small numbers of bacteria that breach epithelial barrier are 
killed by MΦs or can survive briefly in DCs promoting the induc-
tion of IgA by T-dependent and T-independent mechanisms (70). 
Hence, secretory IgA is selectively induced by DCs loaded with 
commensal bacteria resulting in local secretion of IgA that limits 
the penetration and overgrowth of commensal bacteria (71–73). 
The host may as well produce secretory IgA that is pathogen 
specific, but it is believed that indigenous bacteria are bound by 
low-affinity IgA, whereas enteric pathogens are highly coated 
with IgA (74). Flavell group recently demonstrated that GF mice 
colonized with highly IgA-coated taxa from IBD patients were 
much more susceptible to DSS colitis and displayed a bacteria-
enriched inner mucus layer compared to GF mice humanized 
with low IgA-coated bacteria (75). These findings suggest that IgA 
coating is a defense mechanism that the host engages to mark and 
distinguish disease-driven bacteria from other members of the 
intestinal microbiota. The transport of IgA across the intestinal 
epithelium is modulated by the expression of the polymeric 
immunoglobulin receptor (pIgR) on the basolateral membrane 
of IECs. It has been reported that commensal bacteria may 
activate Myd88- and NF-κB-dependent signaling in IECs and 
consequently promote the expression of pIgR (62, 76). In addi-
tion, microbiota-specific TH17 cells may induce epithelial pIgR 
expression, therefore promoting intestinal IgA secretion and 
contributing to intestinal homeostasis. This finding is corrobo-
rated by the evidence that IL-17 receptor-deficient mice display 
reduced IgA levels in the gut that can be restored by TH17 cell 
transfer, and increased bacterial translocation and colitis scores 
upon DSS treatment (77). The serum of CD patients is enriched 
with high levels of IgA autoantibodies (78, 79). Furthermore, CD 
patients harbor a stronger humoral immune response against 
intestinal bacteria than healthy subjects, as shown by the detec-
tion of elevated IgG-coated bacteria in CD stool samples (80). 
This finding corroborates the concept of loss of mucosal tolerance 
for intestinal bacterial communities in CD patients.
Intestinal epithelial cells are currently emerging as key 
mediators of inflammatory and immune mechanisms in mucosal 
tissues. The transcription factor NF-κB has been shown to play 
a crucial role to control epithelial integrity and immune homeo-
stasis toward gut bacteria in gnotobiotic mice and rats (81–83). 
Functional proof for the role of NF-kB signaling in the epithe-
lium was provided by an elegant study from Nenci et  al. (84). 
Mice-harboring IEC deletion of Nemo, upstream modulator 
of NF-κB, displayed destruction of intestinal barrier, dramatic 
translocation of bacteria from the lumen into the mucosa, and 
developed spontaneous colitis that was Myd88 and TNF recep-
tor-1 dependent (84). Consistent with this protective role of 
inflammation-related signaling in the epithelium, the absence 
of TLR-related mechanism conferred increased susceptibility to 
DSS-induced colitis (85).
Nevertheless, the question remains how much TLR-related 
microbial sensing confers protection rather than tissue inflam-
mation. It has been proposed that low expression of TLRs at the 
epithelial level, especially TLR2 and TLR4, is associated with 
mucosal homeostasis by maintaining a hyporesponsive state 
toward the presence of commensal bacteria (86–88). Notably, epi-
thelial tolerance to microbial ligands seems to occur immediately 
after birth in order to promote a stable intestinal host–microbe 
homeostasis (89). Nevertheless, the high turnover rate of the 
epithelium may require additional immunosuppressive media-
tors of the mucosa such as transforming growth factor (TGF)-β 
and prostaglandin (PG) J2 in order to maintain epithelial cell 
homeostasis in response to the constant bacterial challenge (82, 
83, 90). In the context of infectious or chronic inflammatory 
conditions, IFN-γ and TNF-α upregulate TLR expression in 
IECs (91). Consistently, TLR4 is significantly increased on the 
apical side of IECs throughout the lower gastrointestinal tract of 
CD patients (86). With respect to the maintenance of mucosal 
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immune homeostasis, it has also been postulated that the expres-
sion of individual TLR is limited to specific cell lineages (92), 
and it is spatially restricted on the apical or basolateral intestinal 
surface (93, 94). For instance, TLR1, TLR2, and TLR4 seem to be 
coexpressed on a subpopulation of human and mouse cells located 
in the intestinal crypt and belonging to the enteroendocrine 
lineage (92). Analysis of polarized human IECs in vitro indicated 
that TLR5 is expressed on the basolateral surface and from this 
location triggers the production of cytokines and chemokines in 
response to flagellin (93).
Macrophages and DCs sense microbial components of the 
intestinal lumen, providing a key link between the microbiota 
and epithelial barrier functions (95, 96). The primary role of MΦs 
is to phagocytose cellular debris and microbes and stimulate 
lymphocytes and other immune cells to respond to the antigen 
through the secretion of cytokines and chemokines. Depending 
on the requirements of the surrounding tissue environment and 
of the stimuli encountered, MΦs express different biological 
functions exhibiting a remarkable plasticity (97). Gastrointestinal 
mucosal MΦs play a crucial role in maintaining gut homeostasis 
(98). Considering the huge bacterial load present in the intestinal 
lumen, it is likely that commensals (and pathogens) breach the 
epithelium. Mucosal MΦs are strategically located adjacent or in 
proximity of the epithelia and along the lamina propria. Intestinal 
MΦs are characterized by low production of proinflammatory 
cytokines but with an intact phagocytic ability (99). Indeed, this 
MΦ population helps to maintain a low level of inflammation in 
the lamina propria (state of physiologic inflammation), in order 
to prevent inappropriate immune responses to microbes. This is 
possible because intestinal MΦs express low level of TLR2 and 
TLR4, the two main receptors involved in sensing bacterial cell 
wall components (100). However, even though they may express 
TLR1, TLR3, and TLR5–9 to different extents (101), mucosal 
MΦs do not release proinflammatory cytokines in response to 
TLR ligands. They express low levels of TRIF, Myd88, and TRAF6 
proteins, leading to an inability to phosphorylate NF-κB p65 and 
MAPKs (98). Intestinal MΦs retain a highly phagocytic activity, 
but they do not present antigen in normal intestinal mucosa as 
they lack constitutive expression of the costimulatory molecules 
CD40, CD80, and CD86, displaying a tolerance-inducing pheno-
type (98). In contrast, intestinal MΦs from CD patients express 
high levels of costimulatory molecules (102–104), increased acti-
vation of NF-κB signaling and oxidative burst activity (105, 106), 
high expression of TLR2 and TLR4 (107–110), and secretion of 
cytokines, including TNF-α and IL-23 (111).
Dendritic cells located in the lamina propria can penetrate the 
epithelium without disrupting the barrier function and acquire 
antigens from food or directly sample gut-associated bacteria and 
take them to mesenteric lymph nodes, where they are presented 
to CD4+ T cells. In contrast to DCs loaded with harmful bacteria 
that reach systemic secondary lymphoid structures (spleen and 
lymph nodes) and activate systemic immunity, DCs loaded with 
commensal bacteria migrate to the MLNs but remain confined in 
the mucosal lymphoid tissue (112). IECs release mediators (e.g., 
TGF-β, thymic stromal lymphopoietin, and PG E2) that maintain 
DCs in a quiescent state and promote the induction of regulatory 
T cells (113). This mechanism allows the host to develop systemic 
tolerance in response to commensal colonization which appears 
compromised in CD patients (114). During inflammation, IL-12 
and IL-23 produced by DCs restrain regulatory T cells and pro-
mote TH1 or TH17 effector cells, respectively (42). The crucial role 
of IL-23 in promoting chronic mucosal inflammation has been 
emphasized by evidence suggesting that this cytokine, produced 
by innate immune cells, may inhibit FoxP3 Treg cell function and 
consequently positively modulate TH17 differentiation (115).
iLeiTiS PHeNOTYPe iN MOUSe MODeLS 
wiTH DeFiCieNCY iN CROHN’S DiSeASe-
ASSOCiATeD GeNeS
Genetic polymorphisms associated to CD may alter immune 
responses to commensal bacteria and mucosal barrier function 
impacting the microbiota composition in the gut. The possible 
mechanism for genetic regulation of enteric microbiota include 
altered Paneth cell function but also altered barrier functions and 
mucus production, defective secretion of IgA, and altered innate 
and adaptive immune responses.
Paneth cells are specialized IECs located adjacent to the stem 
cell zone in the base of the crypts in the small intestine. They are 
critically involved in host defense against enteric pathogens by 
secreting AMPs and TNF-α (116, 117). Mutations in genes associ-
ated with CD, usually highly expressed in Paneth cells, predispose 
to the development of ileal lesions in humans (118). In line with 
this, mouse model with deficiency in several CD-associated 
genes, including Nod2, Atg16l1, and Xbp1, displays Paneth cell 
defects and susceptibility to intestinal inflammation (119, 120).
Nucleotide-binding oligomerization domain 2 is a well-
acknowledged susceptibility gene for CD (16, 18, 121). NOD2 is 
thought to play a relevant role in maintaining microbial tolerance 
at the intestinal barrier (16) and to activate innate and adaptive 
immunity (63). Three common mutations in the C-terminal 
leucine-rich repeat region of the NOD2 gene, namely G908R, 
R702W, and the frameshift deletion mutation L1007, and several 
other rare polymorphisms have been discovered and associated 
to increased risk of developing CD. How the NOD2 variants 
increase susceptibility to CD remains debated. For instance, the 
frameshift variant L1007 has been shown to decrease NF-κB 
activity in HEK293 cells stimulated with a number of common 
bacteria (17). This observation contradicts the evidence that 
CD clinical specimens are characterized by elevated NF-κB 
activity (122). One possible explanation is that the mutation in 
NOD2 leads to a defect in the innate immune response allow-
ing intracellular bacteria to escape the first line of host defense, 
resulting in an enhanced adaptive response. In support of this 
hypothesis, elevated proinflammatory cytokine production 
was detected in splenocytes and blood mononuclear cells from 
Nod2-deficient mice challenged with TLR2 ligands (123, 124). 
Furthermore, Nod2−/− mice become more susceptible to colitis as 
a result of enhanced TLR2 responses characterized by increased 
production of IL-23 and IL-12 (124). However, the role of NOD2 
as negative regulator of TLR2 is controversial since the same 
L1007 frameshift mutation has been shown to protect mice from 
systemic infection (and inflammation) by Enterococcus faecalis 
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that is a Gram-positive bacterium and therefore sensed mainly by 
TLR2 (125). Notably, Nod2−/− mice do not spontaneously develop 
an inflammatory phenotype (63) but exhibit a higher load of 
commensal bacteria (i.e., Bacteroidaceae) in the terminal ileum 
and Peyer’s patches and a reduced ability to prevent pathogenic 
bacteria colonization (126–128), suggesting a genotype-driven 
selection of a pathobiont-enriched microbiota. Similarly, the 
NOD2 variant L1007 is associated with higher colonization of 
the intestinal mucosa by the Bacteroidaceae in humans (129). It 
is still not clear whether the observed dysbiosis is the cause or a 
consequence of the disease, but it is tempting to speculate that 
NOD2 variants are associated with changes in the composition 
and load of the commensal microbiota in the terminal ileum 
that may facilitate disease progression and pathology. In line 
with this speculation, WT mice develop colitis when recolonized 
with dysbiotic fecal microbiota from Nod2-deficient mice (130). 
In addition, crypts and Paneth cells from Nod2−/− mice have 
attenuated antibacterial activity and decreased expression of 
α-defensin and cryptidin leading to increased susceptibility to 
Listeria monocytogenes infection in vivo (63, 126). These findings 
are in agreement with the deficiency in α-defensin production 
observed in CD patients (3, 131, 132).
In the gut, bacterial growth and division contribute to the 
remodeling of components of the bacterial cell wall, i.e., pepdi-
doglycan (PGN), by bacterial autolysins, e.g., muramidases and 
amidases (133). During this process, soluble PGN fragments can 
be transferred to the bloodstream and initiate innate immune 
responses through PRRs, including NOD2 and TLR2 (134, 135). 
Specific classes of bacteria, such as Actinomyces and Mycobactera, 
use hydroxylases to covalently modify MDP-generating moieties 
that activate more potently the NOD2 pathway. This evidence 
raises the intriguing possibility that bacterial components may 
account for the differential activation of immune cells resulting 
in detrimental effects on a host immunity already compromised, 
such as in CD.
Nucleotide-binding oligomerization domain 2 has been 
reported to account for stem cell protection and to contribute to 
stem cells regeneration via responses triggered by MDP recogni-
tion and leading to the recruitment of NF-κB at the membrane 
surface of IECs (136–139). Conversely, NOD2 mutant 3020insC, 
which is associated with CD, shows an impaired ability to activate 
NF-κB following MDP stimulation in vitro (138, 140, 141). In the 
absence of bacterial invasion into the host cytosolic compartment, 
it has been postulated that MDP can cross plasma membrane and 
localize into the cytosol via the plasma membrane transporter, 
PepT1 (142, 143). During chronic inflammation, such as CD, 
PepT1 expression has been shown to be upregulated in the 
colon (144, 145). Nevertheless, a recent study argues against the 
indication of a role for PepT1 in the development of intestinal 
inflammation, showing that in animal models resembling Crohn-
like ileitis (TNFdeltaARE) and colitis (IL-10−/−, IL-10XTLR2−/−, and 
Rag2−/−) and in human intestinal tissues from IBD patients, 
severity of inflammation correlated with lowered PepT1 expres-
sion levels (146).
Nucleotide-binding oligomerization domain 2 is involved 
in the cellular protection mechanism called autophagy, by 
directly interacting with the ATG16L1. Since both of these genes 
are CD-susceptibility loci, it has been proposed that loss of 
autophaghy-related function is implicated in the pathogenesis 
of CD. DCs (147), MΦs (148), and epithelial cells (149) contain-
ing ATG16L1 and NOD2 variants show defects in antibacterial 
autophagy. In DCs, these defects are associated with an impaired 
ability to process pathogens (such as Salmonella typhimurium) 
and present exogenous antigens (such as MDP) to CD4+ T 
cells (147). Murine Atg16l1- and Nod2-knockout MΦs secrete 
aberrant IL-1β levels in response to LPS (150) and MDP (122), 
respectively. These findings highlight that CD-susceptibility 
genes require interaction with environmental (microbial) cues 
to manifest a disease phenotype. This is further supported by the 
observation that GF hypomorphic Atg16l1 mice are disease free, 
whereas colonized mice display aberrant Paneth cells morphology 
and antimicrobial protein expression, and they are highly suscep-
tible to DSS-induced colitis (119, 150, 151). This phenotype has 
been recently associated to dysfunctional IECs due to mutations 
in the autophagy machinery rather than arising from defects 
in granule formation in Paneth cells (152). In fact, the author 
exploited IECs-specific Atg16l1-knockout mice to demonstrate 
that the deletion of the autophagy-related gene is responsible 
for reduced Paneth cell number, abnormal granule morphology, 
reduced expression of AMPs, and increased inflammation and 
systemic translocation of S. typhimurium compared with control 
mice (152). Similarly, CD patients carrying the ATG16L1 T300A 
mutation show an autophagy-associated defect in Paneth cells 
with granule abnormalities (153). Exploiting mice with epithelial 
cell-specific Myd88 deletion, Hooper group demonstrated that 
only invasive bacteria, such as S. typhimurium and E. faecalis, can 
activate autophagy in IECs in a Myd88-dependent fashion (154). 
In addition, the authors showed that autophagosome formation 
in vivo is TRIF independent, while in RAW MΦs autophagy was 
reported to be depended on this adaptor molecule (155). Nod2−/− 
mice do not harbor defects in autophagosome formation, rather 
lack of the intracellular PRR is associated to an increased number 
of bacteria within ileal IECs compared to WT mice, as shown by 
FISH analysis (154). This finding suggests that bacterial breach 
of the intestinal epithelium triggers autophagy in IECs in Nod2-
independent manner. Mice with an IEC-specific deletion of the 
essential autophagy gene Atg5 display decreased numbers of 
autophagosomes but no histological evidence of pathology and 
an increased number of intracellular S. typhimurium (154). These 
findings highlight the crucial role of IECs as a selective barrier 
that contributes to maintaining mucosal homeostasis by finely 
tuned communications with gut microbiota and the luminal 
environment, peripheral tissues, and the immune system (156).
Multiple cellular stress responses were observed in IBD, 
including endoplasmic reticulum (ER) and mitochondrial 
(mit) unfolded protein responses (UPRs). The accumulation of 
misfolded proteins in the ER and mit lumen of IECs activates 
several processes, including inflammation and UPR signaling 
pathways, and the integrated stress response (157, 158). TLR 
signaling and autophagy cooperate in bacterial sensing actively 
interacting with cellular stress responses, i.e., UPR. UPR signal-
ing is mainly driven by inositol requiring, ER-to-nucleus signal-
ing protein 1α–X-box-binding protein-1 (XBP1) pathway. XBP1 
gene deletion may lead to increased ER stress as a consequence 
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of a defective UPR in secretory IECs (i.e., goblet and Paneth 
cells), thereby affecting their function (120). While Xbp1-
deficient mice are protected from ileitis in GF housing, colonized 
Xbp1−/− mice develop spontaneous transmural inflammation, 
resembling Crohn’s ileitis phenotype in humans (120, 159). In 
particular, mice with Xbp1-deficient IECs develop spontaneous 
enteritis and display ER stress with high level of the chaperone 
grp78 and C/EBP homologous protein (Chop), Paneth cell 
loss, and reduced globlet cell number and size, compromised 
response to pathogenic bacteria (i.e., L. monocytogenes), and 
they are more susceptible to DSS colitis (120). Overexpression 
of CHOP in IECs aggravates DSS-induced colitis and impairs 
mucosal wound healing (160). In vitro, XBP1 deficiency induced 
ER stress that led to a heightened JNK-dependent proinflam-
matory response of epithelial cells to flagellin and TNF-α (120). 
The emerging role of ER stress in the progression of CD is 
supported by the detection of high levels of ER stress markers 
(i.e., grp78) in ileal and colonic epithelia of CD patients (120, 
161, 162). Generation of multiple cellular stress responses, 
and consequently inflammation, in the intestinal epithelium is 
multifactorial and includes genetic and environmental factors 
(163, 164). Paneth cells from patients with quiescent CD and 
healthy controls carrying the ATG16L1 T300A risk allele are 
characterized by increased ER stress (153). This finding indicates 
an interaction between ER stress mechanisms and autophagic 
pathways. For instance, CD patients may harbor a defect in bar-
rier function which results in overactivation of Paneth cells by 
bacterial ligands, requiring a higher demand of secretory AMPs, 
potentially leading to ER stress (165). It is possible to speculate 
that progression of ER stress in CD patients may be facilitated 
by the production of ROS induced by the inflammatory cytokine 
TNF-α (166).
The evidence of barrier dysfunction in CD patients, associ-
ated with the inability to achieve mucosal healing or to seal off 
the damaged epithelium, confers a role of relevance to tight 
junction proteins as risk factors for disease development (167). 
Notably, aberrant (high) tight junction-dependent paracellular 
permeability (168, 169) and exacerbated TNF-α level has been 
observed in CD patients as well as in their healthy first-degree 
relatives (170–173). A proposed mechanism is that inflammatory 
cytokines, i.e., TNF-α, may activate myosin light chain kinase 
(MLCK) which induces tight junction disruption ultimately 
leading to cytoskeletal-related barrier defect (174–177). This 
phenomenon leads to the activation of systemic T cell-mediated 
immune responses and impaired barrier function (178). A 
major validation of this molecular mechanism comes from the 
observation that wild-type mice treated with MLCK inhibitor 
and mlck-knockout mice are protected from barrier dysfunction 
(174, 178). In contrast, transgenic mice expressing mlck consti-
tutively (CA-MLCK Tg) displayed increased paracellular perme-
ability within the small intestine and colon, without developing 
spontaneous disease (179). Intriguingly, transfer of colitogenic T 
cells into CA-MLCK Tg mice accelerated the onset and severity of 
colitis (179). This finding suggests that increased gut permeability 
is insufficient to trigger disease in the absence of other predispos-
ing factors, which most likely include immune dysregulation and 
altered luminal microbiota.
wHAT iS THe CONTRiBUTiON 
OF MiCROBiOTA TO CD?
The microbial composition in the intestinal tract is considered 
another potential risk factor in individuals with CD (51, 180). 
There are several lines of evidence for microbial involvement in 
IBD. For instance, (i) inflammation occurs in regions with higher 
bacterial density, such as distal ileum and colon, (ii) GF animals 
do not develop ileitis (181) or colitis (182), (iii) antibiotics have 
shown some therapeutic efficacy in IBD patients (183), (iv) the 
severity of the disease correlates with the bacterial density in the 
intestinal mucosa, and (v) a large number of studies reported 
an altered bacterial composition in IBD patients compared to 
healthy individuals, so-called dysbiosis (184).
THe GASTRO iNTeSTiNAL 
eCOSYSTeM – wHO iS THeRe?
The mammalian gastrointestinal tract is habitat to taxonomically 
diverse microorganisms in very close proximity to the host. The 
totality of these microorganisms, so-called “microbiota,” includes 
bacteria, viruses, archaea, and eukaryotes (yeasts, protozoa), 
and their genes represent the “intestinal microbiome.” The 
human and murine intestines are dominated by the bacterial 
phyla Bacteroidetes and Firmicutes with a minor proportion 
represented by Proteobacteria, Actinobacteria, Verrucomicrobia, 
Tenericutes, and Fusobacteria (185, 186). At lower taxonomic 
levels, the diversity is very high, with ~100–200 bacterial species 
per individual (187). Notably, great interindividual differences 
were observed in the overall microbial community, highlighting 
the limitation in defining the absolute composition of a “healthy” 
microbiota (188–191). In the last decades, compelling evidence 
emerged pointing out the pivotal role of the intestinal ecosystem 
in defining the host immune homeostasis (e.g., by inducing pro- 
or anti-inflammatory responses) (192). Therefore, the study of 
shifts in the intestinal ecosystem is of fundamental importance 
to understand associations and causalities between gut microbes 
and immunity.
CHARACTeRiSTiCS OF DYSBiOTiC 
eCOSYSTeMS
Under physiological conditions, the microbiota shows both 
plasticity and high resilience, i.e., upon short-term perturbations 
(e.g., change in dietary pattern), the microbial composition 
adapts to alterations in the intestinal milieu, though soon resem-
bles a predisturbance state (189). The microbial ecosystem can 
also be changed without pathologic consequences for the host 
and stabilize within a new “alternative state” (193). Therefore, the 
microbiota is capable of adapting to exposomal factors including 
diet, smoking, antibiotics, or intrinsic factors like host genetics. 
Nevertheless, diet seems capable to overwrite the influence of 
genetic imprint (194–196). Rapid resilience to perturbations is 
a key requirement for the intestinal homeostasis and the host’s 
health in order to maintain a health-associated composition of 
the ecosystem (eubiosis). However, this resilience is lost in some 
November 2015 | Volume 6 | Article 5557
Buttó et al. Dysbiosis vs. Pathobiont Selection in Crohn’s Disease
Frontiers in Immunology | www.frontiersin.org
pathologic conditions, like IBD. In coexistence with genetic sus-
ceptibility to inflammatory processes – like in IBD patients – the 
microbiota is causative for disease development and is therefore 
considered as “dysbiotic” (197).
For different pathologies, there is a strong evidence for the role 
of “dysbiosis,” defined as an alteration in the ecosystem associated 
to pathology (180, 198–200). While for CD and UC, the connec-
tion between dysbiosis and pathology seems well established; also 
other pathologies like obesity, diabetes, cardiovascular disease, 
and even depression or multiple sclerosis have been recently con-
nected to intestinal dysbiosis (198, 201–204)
However, dysbiosis displays several features, which will be in 
the present review categorized in (i) reduced bacterial diversity, 
(ii) expansion of pathobionts, (iii) changes in the microbial 
composition, i.e., increase or reduction in indicator species, and 
(iv) change in microbial functional capacity (205). Thereby, the 
appearance of these characteristics may occur solitarily, succes-
sively, or simultaneously.
The most widely discussed attribute of dysbiosis is reduced 
bacterial diversity. Based on the numbers of bacterial species and 
their abundance found within one sample, the alpha diversity can 
be calculated. Many studies associated lowered bacterial diversity 
to disease, with the rationale of loss in metabolic redundancy 
(180, 206–209). Several reports have addressed dysbiosis and 
decreased diversity in IBD patients’ display compared to healthy 
individuals (51, 180, 200, 206, 210–214). Furthermore, the ability 
to outcompete pathogens by a low-diverse microbiota is dimin-
ished. In patients who underwent frequent antibiotic treatment, 
the deteriorated intestinal diversity was shown to increase the 
risk of infection by opportunistic pathogens, such as Clostridium 
difficile (215). In animal models, pathogens including Salmonella, 
Citrobacter rodentium, or enterohemorrhagic Escherichia coli fail 
to colonize in the presence of a diverse, undisturbed microbiot 
but elicit pathogenic traits if competing strains are missing 
(216–219). The mechanisms of competitive exclusion may 
correspond to rivalry for nutrients or virulence modulation of 
intruding strains (220).
Dysbiosis may also be simplified by linking it to expansion 
of pathobionts, i.e., single strains of the commensal microbiota 
that outgrow and cause detrimental effects in the host. The term 
pathobiont was defined by Chow and Mazmanian as “…symbiont 
that is able to promote pathology only when specific genetic or 
environmental conditions are altered in the host” (221). While 
pathobionts are found only in low abundance in a healthy micro-
bial setting, they overgrow in dysbiosis and cause disease in the 
susceptible (e.g., immune compromised) host. Hereby, specificity 
in the combination of microbe and host susceptibility is required. 
In animal studies, it was shown that Bacteroides vulgatus induced 
colitis in HLA/B27-ß2m rats, but not in IL-10−/− mice and 
even prevented colitis in IL-2−/− mice (222, 223). Early studies 
regarded Mycobacterium avium subspecies paratuberculosis as 
the responsible pathobiont or even pathogen in IBD. However, 
this hypothesis could not be verified, as summarized by Packey 
and Sartor (224). In stool samples and mucosal specimens from 
IBD patients, an increased abundance of Enterobacteriaceae is 
repeatedly observed, and among these the E. coli strain LF82 
is discussed to be a pathobiont (225–227). The group around 
Darfeuille-Michaud was the first to describe adherent-invasive E. 
coli (AIEC), which selectively colonize the ileum of CD patients, 
suggesting that dysbiosis in IBD may also relate to strain-specific 
virulence factors (6, 228–231). The authors showed that the AIEC 
strain LF82 is able to persist within MΦs and epithelial cells and 
selectively colonizes the ileum of CD patients.
Apart from single pathobiont alterations, dysbiosis is in most 
cases regarded as shifts in the overall microbial composition, i.e., 
simultaneous increased or decreased abundance of certain com-
mensals. Due to the new sequencing techniques and improved 
databases, great progress has been made in characterizing the 
intestinal microbiome also in larger cohorts. However, most 
samples were taken from patients who already underwent some 
sort of treatment, which exerts changes in the ecosystem and 
thereby impede conclusive interpretation of findings (232–234). 
A study from Gevers et al. elegantly solved this issue by picturing 
the treatment naive microbiome in children recently diagnosed 
for CD, before shifting the intestinal ecology by different forms 
of pharmaceutical or nutritional intervention. They described 
an increase in Enterobacteriaceae preceding the onset of CD, 
an observation made by other studies as well (199, 234, 235). It 
is worth noting, however, that small inflammatory lesions may 
result in changes in microbiota composition prior to the diagno-
sis of disease. Thus, prospective cohorts would be of high value 
but demanding considering the low incidence of IBD. Among the 
multitude of studies performed to detect IBD-associated bacte-
rial taxa, little congruence is found between different cohorts. 
By combining the sequencing data from several studies, Walters 
et  al. showed shifts in the bacterial composition at different 
taxonomic levels, which were at least partly consistent for several 
studies and cohorts (227). They showed higher abundance of 
Actinobacteria and Bacteroides sp. and a loss of Prevotella sp. in 
CD patients compared to healthy controls. They also described at 
lower taxonomic level the loss of some indicator species in IBD, 
like Faecalibacterium prausnitzii. This health-associated species 
was found in significantly lower levels in the inflamed intestine 
compared to healthy specimens and exerts positive immune-
regulatory effects on the host (236, 237). Therefore, loss of F. 
prausnitzii is speculated to be an indication for increased IBD 
risk (211, 236, 237). However, use of just a single indicator species 
as diagnostic tool may not be sufficient, as IBD-associated strains 
may be cohort or individual specific. Nevertheless, the novel 
approach of using the analysis of overall drifts in the intestinal, 
preferably stool microbiota as a diagnostic tool is a promising 
new tactic in IBD diagnosis. Walters et  al. highlighted some 
universally valid disease-related shifts, which may be powerful 
enough to securely diagnose IBD, by combining the sequencing 
results from several studies (227). By using stool microbiota, this 
non-invasive approach is even more advantageous.
By great advances in 16S rRNA profiling methods, shifts in the 
prevailing bacterial members of the intestinal composition can be 
more easily assessed and discussed. However, most descriptions 
of intestinal dysbiotic communities fail to take fungal and viral 
contributions into consideration. Recently Chehoud et al. could 
show reduced fungal diversity in pediatric CD accompanied by 
increased Candida taxa (238). Norman et al. showed marked dif-
ferences in the intestinal virome in CD and UC patients compared 
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to healthy controls (239). The main difference was an increase in 
Caudovirales bacteriophages which was not secondary to bacte-
rial dysbiosis, but it is more likely to assume that viral dysbiosis 
contributes to pathology and changes in the bacterial ecosystem 
due to a “predator–prey” relationship (240–242). However, stud-
ies of the role of other microbial taxa in IBD pathogenesis are 
awaited and will be essential to unravel dysbiotic patterns.
In addition to bacterial changes in composition and diversity, 
changes in the functional metabolic capacities are characterizing 
a dysbiotic ecosystem on a functional level. As shown by the 
human microbiome project, the healthy intestinal ecosystem may 
be highly different in composition, while its metabolic activity 
is highly similar (190). An interesting study in IBD patients by 
Morgan et al. showed a small perturbation of the intestinal com-
position, though a quite distinct change in microbial function 
(235). In dysbiotic conditions, microbial pathways for oxidative 
stress tolerance, immune evasion, metabolite uptake, and carbo-
hydrate as well as amino acid biosynthesis were upregulated. An 
increase in carbohydrate metabolism and especially changes in 
the metabolic capacity to utilize fucose were reported in dysbiotic 
settings in CD patients or animal models of inflammation by oth-
ers as well (181, 243–245). Metaproteome analysis in a cohort of 
CD patients also proved a distinct protein signature associated to 
CD (246). By correlating these functional shifts to the bacterial 
ecosystem, Bacteroides-derived proteins related to survival in 
challenging environments (e.g., DnaKs and other chaperones) 
were found overrepresented. Dysbiosis may also be described by 
changes in the intestinal microbial function and consecutively 
produced metabolites (247, 248). This leads to the assumption 
that dysbiosis may be more precisely characterized by changes in 
the microbial function rather than composition.
Dietary fibers are often associated to be reducing the IBD 
risk, as fibers are metabolized to short-chain fatty acids (SCFA) 
by microbes in the distal gastrointestinal tract (249). Those 
SCFA were found to hamper the growth of pathogens, increase 
the intestinal barrier function, and serve as energy source for 
colonocytes (250–255). Furthermore, they also facilitate the 
generation and differentiation of regulatory T cells in the gut and 
thereby are important to maintain a homeostatic environment 
(252, 254, 256). Machiels et al. have reported that UC is associated 
with impairment in SCFA production (237). Though the authors 
observed a reduction in butyrate-producing Roseburia hominis 
and F. prausnitzii, as well as a reduction in butyrate levels, they 
could not draw a direct correlation between these findings. This 
provides evidence that the microbiota may not only be divergent 
regarding the abundance of community members but also in 
their metabolic activity.
Furthermore, the definition of dysbiosis should not be a mere 
one-sided microbial consideration but should take the host into 
account as well. Palm et al. showed that IBD patients display an 
altered immune recognition of a dysbiotic microbiota correlating 
with an increased and divergent IgA coating (75). By using an 
animal model of chemically induced colitis, they also transferred 
the disease susceptibility and thereby proved the true causal role 
of this IgA-coated ecosystem. Consequently, dysbiosis may also 
be defined as an “alteration of symbiosis” with pathophysiologic 
consequence (257).
wHAT CAUSeS DYSBiOSiS?
The sum of environmental triggers, so-called exposome, includ-
ing diet, early nutrition (breast or formula feeding), mode of 
delivery, hygienic milieu (contact to disinfectants or animals), 
stress, drugs, lifestyle, and geography (e.g., air pollution and loca-
tion) may contribute to shape the intestinal ecosystem (Figure 1) 
(185, 208, 258–266). Diet has an enormous impact on the intes-
tinal ecology. For instance, diet high in fat shifts the microbiota 
toward a more dysbiotic pattern associated with increased risk 
of intestinal inflammation. David et  al. effectively showed the 
plasticity and the stability of the intestinal ecosystem upon short-
term perturbations by feeding mice an exclusively animal- or 
plant-based diet (267). Animal-based diet promotes bile-tolerant 
microorganisms, such as Alistipes or Bilophila (194, 267). For 
instance, the increase in Bilophila is of interest considering that 
Bilophila wadsworthia was previously shown to exert pathobiont 
behavior in IL-10−/− (268). In another study, a western diet (rich 
in fat and sugar) induced dysbiosis and favored the increase in 
AIEC LF82 upon colonization in genetic susceptible CEABAC10 
mice (269). Several other studies showed that dramatic shifts in 
the intestinal ecosystem are not induced by short-term changes in 
dietary habits or application of single nutrient but require long-
term pressure on the ecosystem (189, 270).
Beside exposomal factors, also intrinsic factors, i.e., host 
genetic, shape the intestinal microbiota. Several genes associated 
with altered immune function, microbial recognition, or antimi-
crobial defense were shown to influence the intestinal ecosystem. 
In a meta-analysis, Knights et al. highlighted the significant asso-
ciation between the NOD2 risk allele and increased abundance 
of Enterobacteriaceae in IBD patients (271). This observation was 
backed up by cohousing experiments of NOD2-deficient mice 
which develop a genotype-induced dysbiosis. By transferring 
this dysbiotic microbiota to WT cage-mates, they became more 
susceptible to DSS colitis (130). In another study, Rausch et al. 
showed an association between the intestinal microbiota and the 
FUT2 (secretor) gene – a physiological trait that regulates gastro-
intestinal mucosal expression of blood group A and B antigens. 
Approximately 20% of humans lack the FUT2 gene, which was 
shown to be a risk factor for CD development (272). Within the 
group of CD patients, the microbiota from FUT2 carriers differed 
from non-secretors in composition, diversity, and functionality 
(245, 273).
In intestinal pathologies, such as IBD, dysbiosis is associated 
to inflammation. It has been proposed that the shift in bacte-
rial composition is due to the inability of some bacterial taxa 
to adapt to the inflammatory milieu characterized by increased 
secretion of AMPs (274). The potential of AMPs to shape the 
intestinal ecology and their importance in IBD has been shown 
by others before (275). The inflammatory process may also 
induce stress or upregulation of virulence-associated genes in 
the microorganism, as shown in monoassociation studies with 
the gut commensal strains E. faecalis OG1RF (276) or E. coli 
NC101 (277, 278). For instance, metalloprotease gelatinase E 
(GelE) secreted by E. faecalis contributes to the development 
of chronic intestinal inflammation in mice that are susceptible 
to intestinal inflammation (IL-10−/− and TNFdeltaARE mice) by 
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impairing epithelial barrier integrity (279). E. faecalis isogenic 
mutants lacking GelE, enterococcal polysaccharide antigen, or 
lipoproteins (Lgt) show significantly decreased inflammation in 
the distal colon of monoassociated IL-10−/− mice and impaired 
TLR2-mediated activation of DCs (276, 279). E. coli NC101 
cells isolated from inflamed IL-10−/− mice displayed upregulated 
bacterial-stress response genes (e.g., heat shock proteins) com-
pared to isolates from WT mice (277, 278). However, inflam-
mation may also promote growth advantages and virulence 
of pathogens. For S. typhimurium, it was shown that the host 
produces tetrathionate under inflammatory circumstances, 
which consequently promotes the ethanolamine utilization 
of S. typhimurium and thereby its colonization fitness (280, 
281). Also nitrate produced by the host during inflammatory 
processes is assumed to promote growth of Enterobacteriaceae. 
Consequently, the often discussed increase of Enterobacteriaceae 
in IBD may also regard as secondary to inflammatory processes 
rather than causative (282).
Apart from host-derived factors, also microbe-derived 
mechanisms exert impact on other commensals. The transfer of 
single strain or bacterial consortia to GF mice enables to study 
mechanisms of microbe–microbe interaction. Commensals are 
capable of inhibiting growth of pathogens by, e.g., competition for 
nutrients, quorum sensing-mediated colonization repression, as 
well as expression of virulence factors (220, 283–285). Metabolic 
interaction (food chain) of commensals and pathobionts are also 
shaping the intestinal ecosystem, as some organisms depend on 
the conversion of dietary components or induction of host-derived 
nutrients by other members of the microbiota (217, 286–288). 
Also quorum sensing-mediated repression of colonization is 
regarded as an important mechanism of shaping the intestinal 
ecosystem, and recent findings from Thompson et  al. demon-
strate the role of autoinducer-2 in reshaping antibiotic-induced 
dysbiosis in the gut (284, 289).
THe ROLe OF THe MiCROBiOTA iN 
ANiMAL MODeLS OF iNTeSTiNAL 
iNFLAMMATiON
Most dysbiosis-influencing factors cannot be studied under 
highly controlled and standardized conditions in humans. To 
discover causative dysbiotic shifts in the microbiota prior to 
disease onset, large prospective cohort screenings would be 
necessary, which are hardly feasible due to low incidence rates. 
Therefore, animal models of intestinal inflammation are gaining 
more and more importance, as confounders like diet, genetic 
background, and hygienic environment can be continuously 
controlled. Genetically driven animal models developing inflam-
mation without any chemical inductor (e.g., DSS or TNBS) are 
especially appropriate to study the interaction of the intestinal 
microbiota and pathology, as the chemical compound per  se 
would influence the ecosystem. Ever since the availability of GF 
and gnotobiotic animal models, great progress has been made 
to portray microbe–host interaction. Hereby, many IBD mouse 
models were shown to be free of disease in GF conditions and 
thereby clearly prove the causality of microbial triggers in IBD 
development.
The IL-10−/− mouse – incapable of producing the anti-inflam-
matory cytokine IL-10 – is the best-studied model of colitis. In 
FiGURe 1 | The different influencing factors and characteristics of dysbiosis. The intestinal microbiota is influenced in diversity, composition, function, and 
prevalence of pathobionts by internal and external factors. Consequently, the microbiota varies in immune relevant characteristics and thereby shifting from a 
eubiotic to a dysbiotic state.
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GF housing, IL-10−/− mice do not develop inflammation, and 
interestingly the time point of microbial colonization seems to be 
of importance, as IL-10−/− mice colonized at adult age developed 
more severe inflammation (182). A more recent model of UC 
is the Rag2−/− ×  Tbx21−/− (TRUC) mouse model. Those mice 
develop UC-like colitis due to the absence of an adaptive immune 
system. TRUC mice were free of colitis in GF conditions as well 
(290). Another model protected from inflammation under GF 
conditions is the TCR alpha-knockout model. These mice are 
characterized by a defective immunity as well, as αß T cells are 
absent (291). Also severe combined immunodeficiency (SCID) 
mice, having an impaired B and T cell functions, are free of colitis 
in GF-housing conditions (292).
However, all the above-mentioned models display a colitis 
phenotype. To study mechanisms relevant in CD, which is 
characterized by ileal involvement, just few animal models are 
available. The SAMP1/YitFc mouse model is one of the rare 
models displaying a CD-like inflammation, with still uncertain 
mechanism of pathology induction (293, 294). Nevertheless, a 
recent study suggests that inflammation may be mediated by 
loss of CCL21 signaling and DC migration from the ileal lamina 
propria to mesenteric lymph nodes (293–297). Another model 
of CD-like ileitis is the TNFdeltaARE mouse model. These mice 
have increased TNF levels due to a deletion of the adenosine–
uracil-rich element in the TNF transcript (298). The pathol-
ogy in TNFdeltaARE mice with their transmural ileitis and the 
Th-1-driven immune response give a very good resemblance 
to the inflammation in CD patients. In line with this, TNF 
antibodies, which are a treatment option in CD patients, were 
shown to hamper inflammation in TNFdeltaARE mice (299). Just 
recently, the necessity of a microbial trigger for inflammation 
development was demonstrated, as TNFdeltaARE mice are free of 
inflammation in GF housing (181). In contrast to SAMP1/YitFc 
mice, the inflammation in TNFdeltaARE mice is not characterized 
by the formation of “cobblestone” structures – a thickening of 
the gut wall with protruding lesions found also in some patients 
with progressive IBD in humans (300, 301). These divergent 
three-dimensional structural inflammatory phenotypes again 
highlight the necessity and basic requirement of different mouse 
models to study the mechanisms of inflammation development 
and to be able to characterize the complexity of inflammation 
in IBD.
Mice with a conditional deletion of caspase 8 (a protease 
involved in apoptosis regulation) in the IECs (Casp8deltaIEC mice) 
spontaneously develop chronic inflammation in the terminal 
ileum due to increased necroptosis (302). Notably, antibiotic-
treated Casp8deltaIEC mice were rescued from ileitis, indicating an 
important role for the intestinal microbiota in the development 
of the disease (303).
Finally, the development of animal models that mirror human 
genetic risk factors for IBD or other pathologies may be an 
important step toward unraveling mechanisms of pathology. The 
disease-free status of animal models in GF housing is exploited as 
valuable tool to investigate the development of dysbiosis, its influ-
encing factors, and also mechanisms of microbe–host interaction 
in gnotobiotic setups.
DYSBiOSiS AND MiCROBe–HOST 
iNTeRACTiON iN GNOTOBiOTiC  
ANiMAL MODeLS
Specific mechanisms of disease induction can be studied through 
the colonization of GF mice with single bacterial strain. Therefore, 
many colonization studies have been performed for models of 
intestinal inflammation as well as for other pathologies, including 
obesity, diabetes, and multiple sclerosis, as recently summarized 
(304). However, by colonizing immunocompromised GF animals 
with selected single strain, several obstacles are met. Not all 
microbes colonize equally, and the induction of inflammation 
depicts bacteria as well as model-specific traits.
In the IL-10−/− model, several monoassociations with candidate 
pathobionts failed to induce inflammation, such as Helicobacter 
hepaticus and E. coli, while other bacteria were effective in devel-
oping pathology, such as E. faecalis or B. wadsworthia (279, 305, 
306). These findings suggest that an association with only one bac-
terial strain may not be sufficient to induce the necessary immune 
maturation required for the establishment of the inflammatory 
status. Atarashi et al. could show that one strain of Clostridium was 
not sufficient to induce regulatory immune functions in former 
GF animals, as this relies on concerted actions of different strains 
(307, 308). It is tempting to speculate that not all members of the 
microbiota are equally sufficient to induce pathology but rather 
requires the interaction with other commensals. An example of 
this hypothesis encompasses monoassociation of IL-10−/− mice 
with H. hepaticus or Lactobacillus reuteri, which as single strain 
did not induce inflammation, while the combination of the two 
bacteria induced colitis (306). Therefore, current studies tend to 
use complex microbial settings or defined microbial consortia to 
ensure sufficient immune maturation in GF animals. Garrett et al. 
showed that colitis in TRUC mice correlates with increased abun-
dance in Klebsiella pneumonia and Proteus mirabilis. However, the 
combined colonization of TRUC or Rag2−/− recipient mice with 
both these two bacterial strains did not induce inflammation. Just 
a combined colonization of K. pneumonia, P. mirabilis, and a com-
plex microbiota induced inflammation in recipient Rag2−/− mice 
(290). However, it has to be mentioned that WT cage-mates were 
also inflamed, suggesting a rather pathogenic than dysbiotic trait 
of the microbiota. Interestingly, Powell et al. identified Helicobacter 
typhlonius as a key driver of pathogenesis in TRUC mice (309). 
The transfer of a complex microbiota from inflamed TRUC mice 
induced colitis in gnotobiotic TRUC mice as well. However, when 
the microbiota from antibiotic-treated mice in remission was 
transferred, the recipients developed only attenuated inflamma-
tion (310). In the SCID mouse model, Stepankova et al. showed 
inflammation development by segmented filamentous bacteria 
(SFB) only in combination with complex specific pathogen-free 
(SPF) microbiota (292). SFB are known to be potent inducers of 
the host’s immune response as summarized elsewhere (292, 311). 
This also points out the fact that monocolonizations may pose 
elegant ways to prove causality, whereas complex mechanisms of 
disease initiation may need more complex interactions. TNFdeltaARE 
mice colonized with the pathobiont E. coli LF82 did not develop 
ileitis, whereas the disease was induced upon colonization with 
November 2015 | Volume 6 | Article 55511
Buttó et al. Dysbiosis vs. Pathobiont Selection in Crohn’s Disease
Frontiers in Immunology | www.frontiersin.org
microbiota from inflamed donors (181). Those mice showed in 
SPF housing high variance in ileitis development due to spon-
taneous shifts in the intestinal microbiota, i.e., inflamed mice 
displayed microbial patterns distinct from non-inflamed mice. By 
transferring the microbiota from inflamed TNFdeltaARE to GF mice, 
the TNFdeltaARE recipients develop inflammation. The WT cage-
mates did not develop inflammation, showing that the microbiota 
was truly dysbiotic and not pathogenic, as susceptibility of the 
host is needed for inflammation development. By transferring 
the microbiota from non-inflamed TNFdeltaARE mice, no inflam-
mation was observed in TNFdeltaARE or WT recipients. This clearly 
pinpoints that the concerted action of a complex microbiota with 
dysbiotic patterns and the genetic susceptibility are precondition 
for the CD-like pathology in this model.
The studies mentioned in this review clearly emphasize the role 
of dysbiosis in intestinal pathology, as well as its multifactorial 
etiology. Until now, no single microbial trait could be identified 
as a clear indicator of a dysbiotic state itself. It was rather shown 
that dysbiosis is characterized by multifaceted variations in com-
munity networks and displays specificity for the respective host 
and inflammatory condition. Several human studies reported 
dysbiosis before onset of disease (234, 312). In animal models 
of intestinal inflammation, the causal relationship of a dysbiotic 
ecosystem in inducing inflammation was effectively shown by 
transferring the microbiota directly or by cohousing animals and 
thereby inducing pathology in recipients (130, 181, 290, 310). 
In these animal models which have different mechanisms of 
pathology induction, a single microorganism is not capable to 
induce tissue inflammation but needs the concerted action of a 
complex microbiota. These observations are further supported by 
the fact that no single pathobiont has been found that is consist-
ently present in different IBD cohorts. More and more studies 
show that dysbiosis is characterized by changes in the microbial 
composition and microbial function rather than mere reduction 
in diversity or expansion of pathobionts. This may also explain 
why by now, no single probiotic treatment was found able to 
restore dysbiosis by administration of just one single probiotic 
strain, suggesting that one single species may not be powerful 
enough revert complex dysbiotic shifts.
ReBiOSiS AS CONCePT FOR CLiNiCAL 
THeRAPY
Even though a high number of studies have been performed 
on the benefits of probiotics in IBD, new meta-analyses show 
no overwhelming or placebo-superior effect (313, 314). Strain-
specific mechanisms were investigated showing the potential of 
probiotics to enhance intestinal barrier integrity, to counteract 
proinflammatory cytokines, or to induce an anti-inflammatory 
immune response (315–317). Newer studies go from single 
probiotic strain or mixtures with low defined numbers to more 
complex setups. In C. difficile-induced infection, fecal microbiota 
transplantation (FMT) seems to be very promising and superior 
to antibiotic treatment regimens (318–322). Hereby, the complex 
fecal microbiota of a healthy donor (often a relative or spouse of 
the patient) is processed, standardized, and subsequently trans-
ferred to the patient by either nasogastric route or colonoscopy. 
Although the bacterial taxa associated with a successful FMT-
donor microbiota have not been discovered yet, the subsequent 
increase in the intestinal microbial diversity of the recipient is 
in most cases associated with recovery (323). However, due 
to the novelty of this treatment approach, appropriate cohort 
numbers and well-controlled trials are to be provided in the 
future. The generation of biobanks for frozen donor microbiota 
(e.g., OpenBiome; Microbiome Health Research Institute Inc.) 
is of utmost importance. A future prospect is FMT capsules for 
therapeutic treatment of infectious diseases, such as C. difficile 
infection, which is currently under development (324). Despite 
the fact that FMT was highly effective in C. difficile infection, its 
therapeutic implementation in IBD is unclear. A recent study by 
Moayyedi et al. showed a superior placebo effect of FMT in UC 
patients, though this effect is donor and time dependent (325). An 
overall analysis of uncontrolled studies with small patient cohorts 
shows limited success for FMT as standard therapy in IBD, and 
the rationale of introducing new antigen pools in a milieu that has 
been overreacting to microbial stimuli is questionable (326, 327).
The causality of dysbiosis in IBD development has been 
reported, but clear compositional patterns and functionality are 
still to be unraveled. These aspects are of importance for basic 
understanding of which consortia may be effective for therapeu-
tic potential. Finally, the intestinal bacterial community is under 
the influence of environmental-, host-, and microbial-derived 
factors, and therefore, microbial composition is not the only trait 
to be considered in order to choose the suitable donor, but also 
the recipient genetic background and the exposome should be 
taken into consideration.
CONCLUSiON AND OUTLOOK
Despite a growing body of evidence suggesting a causative role 
of the intestinal microbiota in CD pathogenesis, the impact of 
bacteria on disease progression, the development of the various 
disease phenotypes, the risk to develop therapy refractoriness, or 
the risk to relapse is completely unclear. An increasing number 
of sequencing studies in human cohorts show associations of cer-
tain bacterial groups and CD development. However, due to the 
nature of the study or high interindividual variation, they often 
lack the possibility to depict mechanisms causal for disease ini-
tiation. Therefore, animal models of intestinal inflammation are 
important to show functionality and to depict characteristics of 
dysbiosis. The possibility to unravel certain mechanisms of inter-
action in animal models of inflammation is generating important 
insights. The role of antigenic surface compounds or microbial-
derived metabolites is of great interest to elucidate mechanisms of 
microbiota-induced shifts in intestinal homeostasis. Even though 
new mouse models were recently generated which display more 
hypothesis-driven mechanisms of intestinal inflammation, it is 
evident the paucity of model organisms that accurately reproduce 
all aspects of multifactorial disease, such as CD.
Questions remain about the reliability of mouse models as 
tool to draw interpretations on human disease. In some cases, 
mouse research has led to major advantages in the ability to treat 
serious conditions. For instance, work on the acute promyelo-
cytic leukemia mouse model resulted in successful treatment 
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